HopeStage
Back to all studies
CompletedNCT04932434

A pilot study of psilocybin for depression and anxiety in Parkinson’s

About this titleRead the official source — NCT04932434
Medication studyAges 40–75United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 40 years to 75 years.

Listed locations
San FranciscoSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: August 15, 2021
Recruitment status
Completed
Enrollment listed in the registry
12
Sponsor
Joshua Woolley, MD, PhD
Sponsor type
Individual investigator
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 40 Years to 75 Years
Official registry ID
NCT04932434
Official title
Show the full official title

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

San Francisco

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Joshua Woolley, MD, PhD.

Who was this study for?

Listed age limits: 40 years to 75 years.

Want to explore more studies?

Explore studies